These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

99 related items for PubMed ID: 20841931

  • 1. [Comparative studies of paclitaxel injection "SAWAI" and Taxol® Injection on pharmacokinetics in dogs and in vitro/vivo antitumor activities].
    Takahashi M, Hosoda M, Takahashi H, Todo S.
    Gan To Kagaku Ryoho; 2010 Sep; 37(9):1699-706. PubMed ID: 20841931
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Pharmacokinetics, biodistribution, efficacy and safety of N-octyl-O-sulfate chitosan micelles loaded with paclitaxel.
    Zhang C, Qu G, Sun Y, Wu X, Yao Z, Guo Q, Ding Q, Yuan S, Shen Z, Ping Q, Zhou H.
    Biomaterials; 2008 Mar; 29(9):1233-41. PubMed ID: 18093646
    [Abstract] [Full Text] [Related]

  • 4. Therapeutic efficacy of anti-Lewis(y) humanized 3S193 radioimmunotherapy in a breast cancer model: enhanced activity when combined with taxol chemotherapy.
    Clarke K, Lee FT, Brechbiel MW, Smyth FE, Old LJ, Scott AM.
    Clin Cancer Res; 2000 Sep; 6(9):3621-8. PubMed ID: 10999754
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Voreloxin, formerly SNS-595, has potent activity against a broad panel of cancer cell lines and in vivo tumor models.
    Hoch U, Lynch J, Sato Y, Kashimoto S, Kajikawa F, Furutani Y, Silverman JA.
    Cancer Chemother Pharmacol; 2009 Jun; 64(1):53-65. PubMed ID: 18931998
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Paclitaxel nanoparticle inhibits growth of ovarian cancer xenografts and enhances lymphatic targeting.
    Lu H, Li B, Kang Y, Jiang W, Huang Q, Chen Q, Li L, Xu C.
    Cancer Chemother Pharmacol; 2007 Feb; 59(2):175-81. PubMed ID: 16718469
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Treatment with paclitaxel alone rather than combination with paclitaxel and cisplatin may be selective for cisplatin-resistant ovarian carcinoma.
    Yamamoto K, Kikuchi Y, Kudoh K, Hirata J, Kita T, Nagata I.
    Jpn J Clin Oncol; 2000 Oct; 30(10):446-9. PubMed ID: 11185891
    [Abstract] [Full Text] [Related]

  • 11. Rhein lysinate suppresses the growth of breast cancer cells and potentiates the inhibitory effect of Taxol in athymic mice.
    Lin YJ, Zhen YS.
    Anticancer Drugs; 2009 Jan; 20(1):65-72. PubMed ID: 19343002
    [Abstract] [Full Text] [Related]

  • 12. Adenovirus-mediated p53 gene therapy and paclitaxel have synergistic efficacy in models of human head and neck, ovarian, prostate, and breast cancer.
    Nielsen LL, Lipari P, Dell J, Gurnani M, Hajian G.
    Clin Cancer Res; 1998 Apr; 4(4):835-46. PubMed ID: 9563876
    [Abstract] [Full Text] [Related]

  • 13. Antitumor efficacy of solid dispersion of paclitaxel prepared by supercritical antisolvent process in human mammary tumor xenografts.
    Shanmugam S, Park JH, Chi SC, Yong CS, Choi HG, Woo JS.
    Int J Pharm; 2011 Jan 17; 403(1-2):130-5. PubMed ID: 20974239
    [Abstract] [Full Text] [Related]

  • 14. Antitumor activity of hydrophilic Paclitaxel copolymer prodrug using locoregional delivery in human orthotopic non-small cell lung cancer xenograft models.
    Zou Y, Fu H, Ghosh S, Farquhar D, Klostergaard J.
    Clin Cancer Res; 2004 Nov 01; 10(21):7382-91. PubMed ID: 15534115
    [Abstract] [Full Text] [Related]

  • 15. STX140 is efficacious in vitro and in vivo in taxane-resistant breast carcinoma cells.
    Newman SP, Foster PA, Stengel C, Day JM, Ho YT, Judde JG, Lassalle M, Prevost G, Leese MP, Potter BV, Reed MJ, Purohit A.
    Clin Cancer Res; 2008 Jan 15; 14(2):597-606. PubMed ID: 18223236
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. [Synergic effects of the combination of VEGF-targeted shRNA and taxol on human prostate cancer DU145 both in vitro and in vivo].
    Li BW, Zhang M, He HW, Zhang SH, Shao RG.
    Yao Xue Xue Bao; 2009 Mar 15; 44(3):296-302. PubMed ID: 19449527
    [Abstract] [Full Text] [Related]

  • 20. Concomitant use of Ad5/35 chimeric oncolytic adenovirus with TRAIL gene and taxol produces synergistic cytotoxicity in gastric cancer cells.
    Chen L, Chen D, Gong M, Na M, Li L, Wu H, Jiang L, Qian Y, Fang G, Xue X.
    Cancer Lett; 2009 Nov 01; 284(2):141-8. PubMed ID: 19447545
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 5.